Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Return on Invested Capital (2021 - 2022)

Ovid Therapeutics (OVID) has disclosed Return on Invested Capital for 3 consecutive years, with 0.43% as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Return on Invested Capital fell 2.0% year-over-year to 0.43%, compared with a TTM value of 0.43% through Mar 2023, down 2.0%, and an annual FY2021 reading of 1.09%, changed N/A over the prior year.
  • Return on Invested Capital was 0.43% for Q1 2023 at Ovid Therapeutics, up from 0.47% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.65% in Q4 2021 and bottomed at 0.47% in Q3 2022.
  • Average Return on Invested Capital over 3 years is 0.22%, with a median of 0.43% recorded in 2023.
  • Peak annual rise in Return on Invested Capital hit -2bps in 2023, while the deepest fall reached -2bps in 2023.
  • Year by year, Return on Invested Capital stood at 0.65% in 2021, then tumbled by -172bps to 0.47% in 2022, then increased by 9bps to 0.43% in 2023.
  • Business Quant data shows Return on Invested Capital for OVID at 0.43% in Q1 2023, 0.47% in Q3 2022, and 0.43% in Q2 2022.